Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Trial to Evaluate the Safety and Tolerability of 68Ga-NRT6020 Injection and 177Lu-NRT6020 Injection in FAP-Positive Participants With Advanced Solid Tumors

NCT06911489 is registered in ClinicalTrials.gov with Chengdu New Radiomedicine Technology Co. LTD. as lead sponsor.

NCT NCT06911489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06911489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Trial to Evaluate the Safety and Tolerability of 68Ga-NRT6020 Injection and 177Lu-NRT6020 Injection in FAP-Positive Participants With Advanced Solid Tumors
Lead sponsor
Chengdu New Radiomedicine Technology Co. LTD.
Phase
Phase 1
Overall status
Recruiting
Start date
November 29, 2025
Completion date
December 31, 2027
Enrollment
132 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor malignancy